Insights

Leveraging the immunological diversity of the PentaMice® platform for COVID-19 antibody discovery

icons/content-types/white paper white paper

Biologics Discovery

Hybridoma technology is a popular method for antibody discovery, but the conventional approach of using a single inbred mouse strain for immunization fails to generate the diversity and antibody titers needed to maximize the discovery of high-quality leads. This white paper introduces an alternative immunization approach — the PentaMice platform, a collection of five wildtype mouse strains bred in-house for increased MHC class II diversity — and highlights how Curia is leveraging it for COVID-19 antibody discovery.

Download our white paper for insights on:

  • The PentaMice platform
  • Discovering SARS-CoV-2 variant-specific antibodies
  • Discovering diverse, high-quality antibodies against SARS-Cov-2

Download the White Paper

Ready to move from idea to impact?

Whether you have a question for our team or an opportunity you’re eager to pursue, one of our experts can help you get started.

Contact Us
More from Curia

icons/content-types/white paper white paper

FDA's Quality Management Maturity Program:
Why should CDMOs adhere to the new CDER's Rating System?

Ensuring the safety and efficacy of pharmaceutical products is paramount in the healthcare industry, making the FDA's Quality Management Maturity (QMM) program and CDER's proposed rating system crucial for Contract Development and Manufacturing Organ...

icons/content-types/white paper white paper

Bispecific antibodies unleashed

Advances in disease biology have led to the burgeoning development of bispecific antibodies (BsAbs), which are synthetic proteins capable of targeting two discrete epitopes from different antigens. Their bispecific functionality offers promising ther...